Efficacy of typhoid conjugate vaccine in Nepal: final results of a phase 3, randomised, controlled trial
Open Access
- 19 October 2021
- journal article
- research article
- Published by Elsevier in The Lancet Global Health
- Vol. 9 (11) , e1561-e1568
Abstract
No abstract availableKeywords
Funding Information
- Bill and Melinda Gates Foundation (OPP1151153)
- Academy of Health Sciences
- National Institute for Health and Care Research
This publication has 21 references indexed in Scilit:
- Seroefficacy of Vi Polysaccharide–Tetanus Toxoid Typhoid Conjugate Vaccine (Typbar TCV)Clinical Infectious Diseases, 2018
- The Typhoid Vaccine Acceleration Consortium (TyVAC): Vaccine effectiveness study designs: Accelerating the introduction of typhoid conjugate vaccines and reducing the global burden of enteric fever. Report from a meeting held on 26–27 October 2016, Oxford, UKVaccine, 2017
- Cost-effectiveness analysis of typhoid conjugate vaccines in five endemic low- and middle-income settingsVaccine, 2017
- The burden of typhoid fever in low- and middle-income countries: A meta-regression approachPLOS Neglected Tropical Diseases, 2017
- Status of paratyphoid fever vaccine research and developmentVaccine, 2016
- Safety and Immunogenicity of a Vi Polysaccharide–Tetanus Toxoid Conjugate Vaccine (Typbar-TCV) in Healthy Infants, Children, and Adults in Typhoid Endemic Areas: A Multicenter, 2-Cohort, Open-Label, Double-Blind, Randomized Controlled Phase 3 StudyClinical Infectious Diseases, 2015
- Undifferentiated Febrile Illness in Kathmandu, NepalThe American Journal of Tropical Medicine and Hygiene, 2015
- Burden of typhoid fever in low-income and middle-income countries: a systematic, literature-based update with risk-factor adjustmentThe Lancet Global Health, 2014
- The Challenges of Vaccine Responses in Early Life: Selected ExamplesJournal of Comparative Pathology, 2007
- The Efficacy of aSalmonella typhiVi Conjugate Vaccine in Two-to-Five-Year-Old ChildrenNew England Journal of Medicine, 2001